FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200562795> ?p ?o ?g. }

• W4200562795 endingPage "478" @default.
• W4200562795 startingPage "472" @default.
• W4200562795 abstract "Abstract: No data on the add-on sacubitril/valsartan (S/V) therapy among cardiac resynchronization therapy with a defibrillator (CRT-D) nonresponder patients are currently available in literature. We conducted a prospective observational study including 190 CRT-D nonresponder patients with symptomatic heart failure with reduced ejection fraction despite the optimal medical therapy from at least 1 year. The primary endpoint was the rate of additional responders (left ventricular end-systolic volume reduction >15%) at 12 months from the introduction of S/V therapy. At the end of the 12 months follow-up, 37 patients (19.5%) were deemed as “additional responders” to the combination use of CRT + S/V therapy. The only clinical predictor of additional response was a lower left ventricular ejection fraction [OR 0.881 (0.815–0.953), P = 0.002] at baseline. At 12 months follow-up, there were significant improvements in heart failure (HF) symptoms and functional status [New York Heart Association 2 (2–3) vs. 1 (1–2), P < 0.001; physical activity duration/day: 10 (8–12) vs. 13 (10–18) hours, P < 0.001]. Compared with the 12 months preceding S/V introduction, there were significant reductions in the rate of HF rehospitalization (35.5% vs. 19.5%, P < 0.001), in atrial tachycardia/atrial fibrillation burden [6.0 (5.0–8.0) % vs. 0 (0–2.0) %, P < 0.001] and in the proportions of patients experiencing ventricular arrhythmias (21.6% vs. 6.3%; P < 0.001). Our results indicate that S/V add-on therapy in CRT-D nonresponder patients is associated with 19.5% of additional responders, a reduction in HF symptoms and rehospitalizations, AF burden, and ventricular arrhythmias." @default.
• W4200562795 created "2021-12-31" @default.
• W4200562795 creator A5001640790 @default.
• W4200562795 creator A5003503228 @default.
• W4200562795 creator A5015211243 @default.
• W4200562795 creator A5020242367 @default.
• W4200562795 creator A5030176430 @default.
• W4200562795 creator A5034394063 @default.
• W4200562795 creator A5038405190 @default.
• W4200562795 creator A5039219453 @default.
• W4200562795 creator A5047270349 @default.
• W4200562795 creator A5048738698 @default.
• W4200562795 creator A5050522038 @default.
• W4200562795 creator A5084975204 @default.
• W4200562795 creator A5087850773 @default.
• W4200562795 date "2021-12-22" @default.
• W4200562795 modified "2023-10-14" @default.
• W4200562795 title "Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients" @default.
• W4200562795 cites W2014678603 @default.
• W4200562795 cites W2113698123 @default.
• W4200562795 cites W2116375266 @default.
• W4200562795 cites W2142631978 @default.
• W4200562795 cites W2313186535 @default.
• W4200562795 cites W2427094903 @default.
• W4200562795 cites W2596797126 @default.
• W4200562795 cites W2770689224 @default.
• W4200562795 cites W2797632651 @default.
• W4200562795 cites W2888762031 @default.
• W4200562795 cites W2915125346 @default.
• W4200562795 cites W2976600700 @default.
• W4200562795 cites W2984631994 @default.
• W4200562795 cites W3015366624 @default.
• W4200562795 cites W3086966813 @default.
• W4200562795 cites W3095940460 @default.
• W4200562795 cites W3121498736 @default.
• W4200562795 cites W3122434964 @default.
• W4200562795 cites W3133992824 @default.
• W4200562795 cites W4249896096 @default.
• W4200562795 doi "https://doi.org/10.1097/fjc.0000000000001202" @default.
• W4200562795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34935699" @default.
• W4200562795 hasPublicationYear "2021" @default.
• W4200562795 type Work @default.
• W4200562795 citedByCount "3" @default.
• W4200562795 countsByYear W42005627952022 @default.
• W4200562795 countsByYear W42005627952023 @default.
• W4200562795 crossrefType "journal-article" @default.
• W4200562795 hasAuthorship W4200562795A5001640790 @default.
• W4200562795 hasAuthorship W4200562795A5003503228 @default.
• W4200562795 hasAuthorship W4200562795A5015211243 @default.
• W4200562795 hasAuthorship W4200562795A5020242367 @default.
• W4200562795 hasAuthorship W4200562795A5030176430 @default.
• W4200562795 hasAuthorship W4200562795A5034394063 @default.
• W4200562795 hasAuthorship W4200562795A5038405190 @default.
• W4200562795 hasAuthorship W4200562795A5039219453 @default.
• W4200562795 hasAuthorship W4200562795A5047270349 @default.
• W4200562795 hasAuthorship W4200562795A5048738698 @default.
• W4200562795 hasAuthorship W4200562795A5050522038 @default.
• W4200562795 hasAuthorship W4200562795A5084975204 @default.
• W4200562795 hasAuthorship W4200562795A5087850773 @default.
• W4200562795 hasBestOaLocation W42005627951 @default.
• W4200562795 hasConcept C126322002 @default.
• W4200562795 hasConcept C164705383 @default.
• W4200562795 hasConcept C203092338 @default.
• W4200562795 hasConcept C2775999527 @default.
• W4200562795 hasConcept C2776034619 @default.
• W4200562795 hasConcept C2776331378 @default.
• W4200562795 hasConcept C2776754050 @default.
• W4200562795 hasConcept C2777387769 @default.
• W4200562795 hasConcept C2778198053 @default.
• W4200562795 hasConcept C2779161974 @default.
• W4200562795 hasConcept C535046627 @default.
• W4200562795 hasConcept C71924100 @default.
• W4200562795 hasConcept C78085059 @default.
• W4200562795 hasConcept C84393581 @default.
• W4200562795 hasConceptScore W4200562795C126322002 @default.
• W4200562795 hasConceptScore W4200562795C164705383 @default.
• W4200562795 hasConceptScore W4200562795C203092338 @default.
• W4200562795 hasConceptScore W4200562795C2775999527 @default.
• W4200562795 hasConceptScore W4200562795C2776034619 @default.
• W4200562795 hasConceptScore W4200562795C2776331378 @default.
• W4200562795 hasConceptScore W4200562795C2776754050 @default.
• W4200562795 hasConceptScore W4200562795C2777387769 @default.
• W4200562795 hasConceptScore W4200562795C2778198053 @default.
• W4200562795 hasConceptScore W4200562795C2779161974 @default.
• W4200562795 hasConceptScore W4200562795C535046627 @default.
• W4200562795 hasConceptScore W4200562795C71924100 @default.
• W4200562795 hasConceptScore W4200562795C78085059 @default.
• W4200562795 hasConceptScore W4200562795C84393581 @default.
• W4200562795 hasIssue "4" @default.
• W4200562795 hasLocation W42005627951 @default.
• W4200562795 hasLocation W42005627952 @default.
• W4200562795 hasLocation W42005627953 @default.
• W4200562795 hasLocation W42005627954 @default.
• W4200562795 hasOpenAccess W4200562795 @default.
• W4200562795 hasPrimaryLocation W42005627951 @default.
• W4200562795 hasRelatedWork W2604998822 @default.
• W4200562795 hasRelatedWork W2948540269 @default.
• W4200562795 hasRelatedWork W2955699465 @default.

• next